ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights
-- Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected -- -- Launching second trial of avacopan in patients with C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN …